Equities Analysts Set Expectations for ResMed Q2 Earnings

ResMed Inc. (NYSE:RMD) – Equities research analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of ResMed in a report released on Thursday, December 5th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.25 per share for the quarter, up from their previous forecast of $2.24. The consensus estimate for ResMed’s current full-year earnings is $9.28 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.28 EPS, Q4 2025 earnings at $2.35 EPS, FY2025 earnings at $9.08 EPS, Q2 2026 earnings at $2.33 EPS, Q3 2026 earnings at $2.48 EPS, FY2026 earnings at $9.54 EPS, Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.48 EPS.

Several other research firms have also issued reports on RMD. Baird R W upgraded ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a report on Friday, October 25th. Robert W. Baird upped their price target on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Finally, Royal Bank of Canada raised their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $225.70.

ResMed Stock Up 0.8 %

ResMed stock opened at $241.41 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. The company’s 50-day moving average is $242.30 and its 200-day moving average is $226.57. The firm has a market capitalization of $35.44 billion, a PE ratio of 31.97, a P/E/G ratio of 1.79 and a beta of 0.68. ResMed has a fifty-two week low of $162.05 and a fifty-two week high of $260.49.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $1.64 earnings per share.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.88%. ResMed’s dividend payout ratio is 28.08%.

Insider Activity at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the sale, the director now directly owns 81,218 shares in the company, valued at approximately $19,951,201.70. This trade represents a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 14,683 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $231.91, for a total transaction of $3,405,134.53. Following the transaction, the chief executive officer now owns 464,169 shares of the company’s stock, valued at approximately $107,645,432.79. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 52,725 shares of company stock valued at $12,516,248 over the last three months. 0.71% of the stock is owned by insiders.

Institutional Trading of ResMed

A number of hedge funds have recently made changes to their positions in the company. UMB Bank n.a. raised its holdings in ResMed by 1.9% in the 3rd quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock valued at $602,000 after buying an additional 47 shares during the last quarter. Ascent Group LLC raised its stake in shares of ResMed by 1.7% during the third quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider’s stock valued at $714,000 after acquiring an additional 48 shares during the last quarter. SkyView Investment Advisors LLC lifted its holdings in shares of ResMed by 2.0% during the third quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider’s stock worth $637,000 after purchasing an additional 51 shares during the period. QRG Capital Management Inc. grew its stake in shares of ResMed by 4.5% in the second quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock worth $247,000 after purchasing an additional 56 shares during the last quarter. Finally, Inspire Advisors LLC increased its holdings in ResMed by 1.9% in the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock valued at $586,000 after purchasing an additional 56 shares during the period. 54.98% of the stock is owned by institutional investors and hedge funds.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.